{"entity":{"id":"nct07551349","kind":"trial","name":"Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma","aka":[],"tldr":"A phase 1/2 trial of Fludarabine in renal cell carcinoma, run by Beijing Biotech, now recruiting.","summary":"Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT07551349 by Beijing Biotech, with 36 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: EB-701/CA9-NK, Fludarabine. Conditions listed: Advanced or Metastatic Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07551349","url":"https://clinicaltrials.gov/study/NCT07551349"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["fludarabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07551349","phase":"1/2","setting":"An Open-Label, Multicenter, Phase 1/2 Study of Allogeneic Dual-target CD70/CAIX (CA9) Chimeric Antigen Receptor Natural Killer Cells in Adults With Advanced or Metastatic Clear Cell Renal Cell Carcinoma","sponsor":"Beijing Biotech","enrolled":36,"outcomes":[]},"route":"/trials/nct07551349/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}